PRESCRIBING INFORMATION

Cytacon (cyancobalamin) tablets and syrup

Composition: Each tablet contains 50 micrograms Cyancobalamin BP.

One 5ml spoonful of the syrup contains 35 micrograms of Cyanocobalamin.

Therapeutic indications: Treatment of nutritional Vitamin B12 deficiency, vitamin B 12 deficiency following partial gastrectomy, tropical sprue, alone or with folic acid, pernicious anaemia when parenteral administration is not possible or not advised. Posology and method of administration: For oral administration. Tablets: Adults: One to three tablets or more daily at the discretion of the physician. Alternatively, one or two 5ml spoonfuls of Cytacon liquid two or three times daily, or more at the discretion of the physician. In pernicious anaemia, intramuscular therapy is preferable for initial correction of vitamin B 12 deficiency, may be followed by 300mcg daily orally. **Elderly:** The dosage for tablets is the same as that for adults. For the syrup, one or two 5ml spoonfuls two or three times or more daily at the discretion of the physician. **Children:** One tablet daily at the discretion of the physician. For the syrup, one 5ml spoonful two or three times or more daily at the discretion of the physician. **Contra-indications:** Hypersensitivity to the product or any of the excipients. **Special warnings and special precautions for use:** For pernicious anaemia, an adequate dose must be used and the blood picture must be examined regularly at least every three months for 18 months until stabilised, and then annually. Indiscriminate administration of Cytacon may mask precise diagnosis. **Interactions with other**

medicinal products and other forms of interaction: Paraaminosalicylic acid, colchinine, biguanides, neomycin, cholestyramine, potassium chloride, methyldopa, and cimetidine may reduce absorption of Cyatacon. Treatment with chloramphenicol may lead to poor response to Cytacon. Oral contraceptives may lower serum levels of Cyatacon. Pregnancy and Lactation: Avoid as treatment of megaloblastic anaemia of pregnancy because this is due to folate deficiency. Undesirable **Effects:** Sensitisation to cvancobalamin is rare, but may present as an itching exanthema, and exceptionally as anaphylactic shock. Acneform and bullous eruptions have been reported rarely. Patients who have become sensitised to cyanocobalamin by injection are often able to tolerate cyancobalamin by the oral route without trouble. **Overdose:** Is unlikely to require treatment.

Please refer to the Summary of Product Characteristics for detailed information.

Legal category: P

Basic NHS list price: £6.24 for 50 tablets and £6.24 for

per bottle of 200mls

 $\textbf{Marketing Authorization Number:} \ PL\ 10972/0028, \ PL$

10972/0029

Marketing Authorization Holder: Amdipharm Mercury

Company Limited, NLA Tower,

Croydon, CRO OXT, Trading as Mercury Pharmaceuticals

Date of Preparation: July 2012 **Date of Revision:** June 2013

Adverse events should be reported to the local regulatory authority. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to

Amdipharm Mercury Medical Information on 08700 70 30 33 or by email to medicalinformation@amcolimited.com